A. DeGortari

Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer

T. Kuczek, L. Glickman, D. Knapp, 2000, Cancer Chemotherapy and Pharmacology.

Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.

B. Craig, P. Snyder, D. Knapp, 2002, Cancer research.

Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder.

T. Kuczek, D. Knapp, N. Glickman, 1997, Journal of veterinary internal medicine.

Preclinical evaluation of zinc phthalocyanine tetrasulfonate-based PDT

Michael D. Lucroy, Antonella Borgatti-Jeffreys, Stephen B. Hooser, 2005, SPIE BiOS.

Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.

B. Craig, P. Snyder, D. Knapp, 2003, Molecular cancer therapeutics.

Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma.

D. Knapp, P. Bonney, M. D. Lucroy, 2005, Journal of the American Animal Hospital Association.

Near infrared imaging to identify sentinel lymph nodes in invasive urinary bladder cancer

Larry G. Adams, Jose Ramos-Vara, John V. Frangioni, 2006, SPIE BiOS.

Antitumor effects of piroxicam in spontaneous canine invasive urinary bladder cancer, a relevant model of human invasive bladder cancer.

D. Knapp, P. Bonney, N. Glickman, 2002, Advances in experimental medicine and biology.